Avalon GloboCare Corp. (NASDAQ:ALBT) Short Interest Update

Avalon GloboCare Corp. (NASDAQ:ALBT) was the target of a significant decrease in short interest during the month of August. As of August 31st, there was short interest totalling 221,600 shares, a decrease of 91.3% from the August 15th total of 2,550,000 shares. Approximately 3.7% of the company’s stock are sold short. Based on an average daily trading volume, of 4,410,000 shares, the days-to-cover ratio is currently 0.1 days.

Avalon GloboCare Stock Performance

NASDAQ:ALBT opened at $0.25 on Friday. The company’s 50-day simple moving average is $0.35 and its 200-day simple moving average is $0.36. Avalon GloboCare has a fifty-two week low of $0.24 and a fifty-two week high of $1.44.

Avalon GloboCare (NASDAQ:ALBT) last posted its earnings results on Monday, August 19th. The company reported ($0.19) EPS for the quarter. The company had revenue of $0.33 million for the quarter.

Avalon GloboCare Company Profile

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells.